A Study of Avastin (Bevacizumab) Added to a Chemotherapeutic Regimen in Patients With Metastatic Pancreatic Cancer

• Status: Completed
• Trial end date: 2008-10-01
• Target enrollment: 0
• Participant gender: All

Summary

This study will evaluate efficacy, safety and tolerability of Avastin versus placebo added to a chemotherapeutic regimen in patients with metastatic pancreatic cancer. The anticipated time of study treatment is until confirmed evidence of disease progression, and the target sample size is 500+ individuals.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Hoffmann-La Roche
• Treatments: Bevacizumab

Criteria

Inclusion Criteria:

• adult patients, >=18 years of age;

• metastatic pancreatic cancer (adenocarcinoma);

• good liver, kidney, and bone marrow function.

Exclusion Criteria:

• previous systemic treatment for metastatic pancreatic cancer;

• pregnant or lactating females;

• fertile men, or women of childbearing potential, not using adequate contraception;

• major surgical procedure, open biopsy, or significant traumatic injury within 28 days prior to study treatment start;

• current or recent treatment (within 30 days prior to starting study treatment) with another investigational drug, or participation in another investigational study.